Patients with a BMI between 35 and 39.9 are increasingly being targeted for pharmacological treatment to prevent progression to more severe obesity and related complications
The change in body weight from baseline was 13.3% and 2.6% in the semaglutide and placebo groups, respectively
[1] Fielding, R., Riede, L., Lugo, J., & Bellamine, A
Each component is associated with a different area of research, allowing the provider to consider several wellness goals within one personalized plan
Individuals keen on using supplements as well as sunscreen
This compositional variability, especially given the factors to which proteins are exposed during processing, makes post-harvest preservation technologies critically important